BIIB - Biogen inks $1.8B deal to acquire immune drug developer HI-Bio
2024-05-22 08:42:49 ET
More on Biogen
- Biogen: Reasons To Be Cheerful After Upbeat Q1 Earnings
- Biogen: Don't Overthink This One
- Biogen's Revenue Dip Meets Cost Cuts In Q1 (Rating Upgrade)
- Biogen also drops collaboration with Ionis on Angelman syndrome candidate
- Biogen and Ionis drop ALS candidate after trial setback